Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
This study is currently recruiting participants.
Verified March 2013 by Novartis
Study NCT01576666   Information provided by Novartis

First Received on April 10, 2012.   Last Updated on March 7, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Dose Escalation
Safety
Preliminary Efficacy
Advanced Solid Tumors
Metastatic Breast Cancer
Advanced Pancreatic Adenocarcinoma
Metastatic Colorectal Cancer
Recurrent Glioblastoma Multiforme
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Breast Neoplasms
Colorectal Neoplasms
Glioblastoma
Neoplasms
More general conditions related to this trial
Astrocytoma
Breast Diseases
Carcinoma
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Glioma
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Rectal Diseases
Skin Diseases
Interventions listed in this trial
LDE225
BKM120
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services